On July 2024, Alpha received approval by the FDA of its New Drug Application (NDA) for ZUNVEYL for the treatment of mild-to-moderate Alzheimer’s disease. Alpha will now focus on the development of ...
Adults with attention-deficit/hyperactivity disorder, or ADHD, who use an extended-release medication are more likely to continue the treatment and have a lower risk of developing substance use ...
Today, Mayor London Breed and Supervisor Rafael Mandelman announced findings and recommendations from the Residential Care and Treatment Workgroup, first convened in May 2024 to address the shortage ...